Table 2. Results of univariate and multivariate analysis of factors affecting survival.
| Factor | OS (95% CI) |
p value (for univariate analysis) |
p value (for multivariate analysis) |
|---|---|---|---|
| Completion of CT | |||
| Yes (n = 24) | 23.8 (13.6–34.1) | 0.000 | 0.000 |
| No (n = 22) | 5.9 (1.7–10.1) | ||
| Site of metastasis* | |||
| Nodal (n = 13) | 26.2 (11.8–40.5) | 0.034 | 0.001 |
| Visceral (n = 9) | 9.2 (7.3–11.1) | ||
| Combined (n = 22) | 8.4 (2.0–14.8) | ||
| Response to therapy** | |||
| SD/PD (n = 15) | 5.9 (2.4–9.4) | 0.028 | 0.843 |
| CR/PR (n = 26) | 17.2 (11.8–22.6) | ||
| DFI | |||
| Less than 1 year (n = 9) | 8.4 (0.0–18.6) | 0.106 | NA |
| More than 1 year (n = 37) | 14.9 (6.7–23.2) | ||
| Age | |||
| Less than 50 years (n = 21) | 14.9 (6.4–23.5) | 0.305 | NA |
| More than 50 years (n = 25) | 9.0 (3.8–14.2) | ||
| Symptomatic relapse | |||
| Yes (n = 15) | 9.2 (6.1–12.4) | 0.191 | NA |
| No (n = 31) | 12.6 (2.6–22.6) | ||
| Histology | |||
| Squamous (n = 37) | 11.8 (5–18.6) | 0.598 | NA |
| Non SCC (n = 9) | 17.2 (7.6–26.8) | ||
| Cisplatin upfront | |||
| Yes (n = 37) | 9.5 (4.8–14.2) | 0.628 | NA |
| No (n = 9) | 14.9 (5.7–24.2) | ||
*
Excluding the two patients with isolated local recurrence
**
Excluding the five patients whose response could not be assessed